The effects of eticlopride and the selective D3-antagonist PNU 99194-A on food- and cocaine-maintained responding in rhesus monkeys.
The dopamine D3 receptor is mainly expressed in regions of the brain associated with the limbic system. D3 receptor blockade may antagonize cocaine reinforcement while producing less severe extrapyramidal side effects than blockade of D2 receptors. The purpose of the present studies was to evaluate the effects of a selective D3 receptor antagonist and a non-selective D2/D3 receptor antagonist on food- and cocaine-maintained responding under two schedules of cocaine self-administration. Adult male rhesus monkeys were trained to respond under multiple schedules of food (1.0 g pellets) and cocaine (0.01-0.3 mg/kg/injection) presentation. In one experiment (n=4), the schedule was a fixed-interval (FI) 3-min and a second study (n=6) was conducted using a second-order fixed-ratio 5 (FI 6-min:S) schedule. The D3 antagonist PNU 99194-A (0.3-3.0 mg/kg), which is 14-fold selective for D3 relative to D2 receptors, or the D2/D3 antagonist eticlopride (0.001-0.03 mg/kg) was administered immediately prior to the experimental session for at least 5 consecutive sessions. Under the multiple FI 3-min schedule of food and cocaine presentation, PNU 99194-A and eticlopride decreased food- and cocaine-maintained responding in a dose-dependent manner and irrespective of cocaine dose. Under the multiple second-order schedule of food and cocaine presentation, at least one dose of PNU 99194-A and eticlopride decreased cocaine- and food-maintained responding. These findings indicate that PNU 99194-A can decrease operant responding in monkeys, but not in a manner that would suggest selectivity of cocaine- over food-maintained responding. Future studies with more selective D3 antagonists are needed to better address the role of this receptor subtype in cocaine addiction.
Claytor
Renee
R
Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1083, USA.
Lile
Joshua A
JA
Nader
Michael A
MA
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D003042:Cocaine / Q000008:administration & dosage; D018492:Dopamine Antagonists / Q000494:pharmacology*; D065127:Dopamine D2 Receptor Antagonists; D005502:Food; D007189:Indans / Q000494:pharmacology*; D008253:Macaca mulatta; D008297:Male; D050637:Receptors, Dopamine D3 / Q000037:antagonists & inhibitors; D012055:Reinforcement Schedule; D012054:Reinforcement, Psychology; D012457:Salicylamides / Q000494:pharmacology*; D012646:Self Administration
D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D007189:Indans; D050637:Receptors, Dopamine D3; D012457:Salicylamides; C086335:(5,6-dimethoxyindan-2-yl)dipropylamine; D003042:Cocaine; C045989:eticlopride